Our company
Who are we?
SPyDiag
SPyDiag is a research and development company
specialized in diagnostic and therapeutic innovation
Created in Tours, France at the beginning of 2020, SAS SPyDiag wishes to develop antibodies for diagnostic and therapeutic purposes to fight against viral infections.
To achieve this, the company relies on the know-how and technology developed within the “Biology of Polyomavirus Infections” team (JRU 1282 ISP – University of Tours – INRAe) led by Professor Antoine Touzé and The virology team of the “Infectious Agents, Resistance and Chemotherapy” unit (University of Amiens – Amiens University Hospital) led by Professor Etienne Brochot
From R&D to products
Based on the research work carried out in the Biology of Polyomavirus Infection team, UMR1282 ISP University -INRAe and the Infectious Agents, Resistance and Chemotherapy team, SPyDiag has developed a diagnostic product, UriFastBK, and a therapeutic product, BKNeutrol . Discover the chronology of their development.
2018
Selection and characterization of antibodies recognizing all BK virus genotypes
2019
Selection and characterization of antibodies that NEUTRALIZE genotypes I and IV of the BK virus
2020
SPyDiag’s creation
Signature of a license with the Tours – Amiens universities
Proof of concept of the UriFastBK diagnostic test
2021
National and Regional Phase (Europe/USA) of the diagnostic patent
Signature of the collaboration contract with the Tours – Amiens universities
2023
Specificity and sensitivity test of the UriFastBK test
2024
Arrival of Bertrand de Castelnau as CEO
Construction of the Bi-Specific antibody and filing of the patent
Publication of diagnostic patent No. US2022396612
2025
Diagnostic clinical trial (new European regulation (2017/746) for DM-IVD)
Obtaining CE marking (regulatory monitoring by the company ISOcèle)
Regulatory toxicity bispecific antibody
2026/2027
Phase I clinical trial specific antibody
Reasons to choose SPyDiag
Our strengths
Currently there is no BK virus antigenic test on the market. SPyDiag, thanks to its UriFastBk rapid test, offers early detection of the virus for greater comfort for patients.
SPyDiag is able to offer management of the disease in its entirety: from monitoring the reactivation of the BK virus in urine to therapeutic treatment of the patient.
No specific treatment for BK virus is currently available, only modulation of immunosuppressive treatment is practiced. SPyDiag offers first-in-class therapy
Our team, with multiple and complementary skills, is spread across three different geographic sites, all close to large hospital centers.
